Germany Comes Out on Top as a Leading Manufacturer of Biopharmaceutical Products
According to the latest Biotech-Report for Germany conducted by Boston Consulting Group for VFA Bio, Germany remains the second largest manufacturer of active biopharmaceutical substances licenced by the European Union, with biopharmaceutical sales accounting for 30.8% of the overall medicines market. Based on the current study, biopharmaceutical sales (in the pharma and hospital sector) reached €14.6 billion in 2020, up 14% from the previous year.
View full press release